These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2317 related items for PubMed ID: 10813727

  • 21. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M.
    J Clin Oncol; 2011 Nov 10; 29(32):4227-33. PubMed ID: 21990405
    [Abstract] [Full Text] [Related]

  • 22. Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol.
    Hakvoort-Cammel FG, Buitendijk S, van den Heuvel-Eibrink M, Hählen K.
    Pediatr Blood Cancer; 2004 Jul 10; 43(1):8-16. PubMed ID: 15170884
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Fertility in males treated for Hodgkins disease with COPP/ABV hybrid.
    Hobbie WL, Ginsberg JP, Ogle SK, Carlson CA, Meadows AT.
    Pediatr Blood Cancer; 2005 Feb 10; 44(2):193-6. PubMed ID: 15390272
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.
    Haematologica; 1998 Sep 10; 83(9):812-23. PubMed ID: 9825578
    [Abstract] [Full Text] [Related]

  • 29. Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group.
    Glick JH, Barnes JM, Bakemeier RF, Prosnitz LR, Bennett JM, Neiman RS, Costello W, Orlow EL.
    Cancer Treat Rep; 1982 Apr 10; 66(4):855-70. PubMed ID: 7042087
    [Abstract] [Full Text] [Related]

  • 30. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA.
    J Clin Oncol; 2003 Feb 15; 21(4):607-14. PubMed ID: 12586796
    [Abstract] [Full Text] [Related]

  • 31. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O, Hasenclever D, Loeffler M, Diehl V, German Hodgkin's Lymphoma Study Group.
    Ann Hematol; 2004 Mar 15; 83(3):176-82. PubMed ID: 15064867
    [Abstract] [Full Text] [Related]

  • 32. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 Oct 01; 21(19):3601-8. PubMed ID: 12913100
    [Abstract] [Full Text] [Related]

  • 33. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH, Wang SS, Huang Y, Wang B, Huang HQ, Zhang L, Sun XF, Xu RH, Lin TY.
    Ai Zheng; 2006 Aug 01; 25(8):1013-8. PubMed ID: 16965685
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi.
    N Engl J Med; 2011 Jul 21; 365(3):203-12. PubMed ID: 21774708
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
    Villani F, Busia A, Villani M, Laffranchi A, Viviani S, Bonfante V.
    Anticancer Res; 2009 Feb 21; 29(2):777-83. PubMed ID: 19331235
    [Abstract] [Full Text] [Related]

  • 39. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA.
    N Engl J Med; 1992 Nov 19; 327(21):1478-84. PubMed ID: 1383821
    [Abstract] [Full Text] [Related]

  • 40. Hodgkin's disease: summary of twenty years' experience.
    Mazza P, Bocchia M, Zinzani PL, Fiacchini M, Gherlinzoni F, Bandini G, Bendandi M, Frezza GP, Neri S, Barbieri E.
    Haematologica; 1992 Nov 19; 77(6):487-93. PubMed ID: 1283856
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 116.